US5350571A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Emulsions of highly fluorinated organic compounds
Assignee: Hemagen PFC LP
•
Filing: 1992-02-24
•
Granted: 1994-09-27
•
Expires: 2012-02-24
Abstract
Abstract Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic compound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components.
Inventors
- 👤 Robert J. Kaufman
- 👤 Thomas J. Richard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:47
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A61K31/00; A61K31/02; Y; Y10; Y10T; Y10T436/00; Y10T436/24
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
198 words
A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 400 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 400 nm after 5 days in serum or ionic solutions, (3) an LD 50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 4° c.
Claim 2
Dependent Claim
198 words
A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 400 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 400 nm after 5 days in serum or ionic solutions, (3) an LD 50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 4° c.
Claim 3
Dependent Claim
198 words
A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 300 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 300 nm after 5 days in serum or ionic solutions, (3) an LD 50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 25° C.
Claim 4
Dependent Claim
198 words
A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 300 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 300 nm after 5 days in serum or ionic solutions, (3) an LD 50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 25° C.
Claim 5
Dependent Claim
31 words
The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is present in the emulsion in an amount between about 30% and about 55% by volume.
Claim 6
Dependent Claim
25 words
The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is present in the emulsion in about 40% by volume.
Claim 7
Dependent Claim
25 words
The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is selected from the group consisting of perfluorooctylbromide and perfluorodecalin.
Claim 8
Dependent Claim
24 words
The contrast agent according to claim 1 or 2, wherein the oil is selected from the group consisting of safflower oil and soybean oil.
Claim 9
Dependent Claim
16 words
The contrast agent according to claim 1 or 2, wherein the surfactant is egg yolk lecithin.
Claim 10
Dependent Claim
32 words
The contrast agent according to claim 1 or 2, further comprising at least one compound selected from the group consisting of isotonic agents, osmotic pressure controlling agents, serum extending agents and antioxidants.
Claim 11
Independent Claim
53 words
A method for non-invasive imaging of internal organs and bloodflow comprising the step of administering to a patient in a pharmaceutically acceptable manner a contrast agent selected from the contrast agents of claims 1 or 2 in conjunction with an imaging modality selected from magnetic resonance imaging, ultrasound, positron emission tomography and x-ray.
References Cited (Backward Citations)
US2055083A
Cited
US3793450A
Cited
US3958014A
Cited
US3975512A
Cited
US3823091A
Cited
US3942527A
Cited
US3778381A
Cited
US3914294A
Cited
US3911138B1
Cited
US3911138A
Cited
US3962439A
Cited
FR2246262A1
Cited
US3989843A
Cited
US4073879A
Cited
US4073943A
Cited
US4105798A
Cited
US4186253A
Cited
US4285928A
Cited
US4252827A
Cited
US4366169A
Cited
US4325972A
Cited
EP0051526A1
Cited
US4569784A
Cited
FR2494992A1
Cited
US4486417A
Cited
US4395393A
Cited
JPS5832829A
Cited
EP0080716A2
Cited
US4599343A
Cited
US4591599A
Cited
US4526969A
Cited
US4562183A
Cited
US4446154A
Cited
EP0089232A2
Cited
US4452818A
Cited
US4461717A
Cited
US4443480A
Cited
US4397870A
Cited
US4423077A
Cited
US4497829A
Cited
US4542147A
Cited
US4423061A
Cited
US4425347A
Cited
US4534978A
Cited
WO1984003624A1
Cited
EP0144434A1
Cited
EP0158996A2
Cited
WO1986000810A1
Cited
US4657532A
Cited
EP0220153A1
Cited
EP0220152A1
Cited
US4865836A
Cited
US5080885A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-26 | 1998-03-28 | 1998-09-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-26 | 2002-03-28 | 2002-09-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-26 | 2006-03-28 | 2006-09-27 | $7700.00 | Window Closed / Lapsed |